---
title: "Starling Oncology director Brad Hively to step down as vice chairman, not seek re-election in 2027"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297766159.md"
description: "Starling Oncology director Brad Hively has stepped down as vice chairman and left all committee roles, including the compliance committee. He will remain on the board until the 2027 annual stockholders meeting but will not seek re-election at that time."
datetime: "2026-09-02T10:05:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297766159.md)
  - [en](https://longbridge.com/en/news/297766159.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297766159.md)
generator: "portal-rs"
---

# Starling Oncology director Brad Hively to step down as vice chairman, not seek re-election in 2027

-   Starling Oncology director Brad Hively will not stand for re-election at the 2027 annual stockholders meeting. \* He will remain on the board until the meeting. \* Effective immediately, Hively stepped down as vice chairman. \* He also left the compliance committee, ending all committee roles. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starling Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001208), on September 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [STLN.US](https://longbridge.com/en/quote/STLN.US.md)

## Related News & Research

- [Starling Oncology Q3 revenue rises on specialty pharmacy growth; narrows 2026 outlook](https://longbridge.com/en/news/304534200.md)
- [The Oncology Institute GAAP EPS of -$0.14 misses by $0.09, revenue of $169.8M beats by $1.11M](https://longbridge.com/en/news/304532840.md)
- [QBTS: Revenue rose 21%; nine-month bookings surged 611% as adjusted losses widened](https://longbridge.com/en/news/305007924.md)
- [What's Going On With Trade Desk Stock Tuesday?](https://longbridge.com/en/news/304999508.md)
- [‘The Worst May Not Be Over,’ Says Investor About Rocket Lab Stock](https://longbridge.com/en/news/304905914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**